288 related articles for article (PubMed ID: 29634142)
1. [Combination drug therapy in patients with BPH].
Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
[TBL] [Abstract][Full Text] [Related]
2. [Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines].
Vinarov AZ; Spivak LG; Mironov AV
Urologiia; 2017 Sep; (4):120-128. PubMed ID: 28952704
[TBL] [Abstract][Full Text] [Related]
3. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
4. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
6. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
Haillot O; Fraga A; Maciukiewicz P; Pushkar D; Tammela T; Höfner K; Chantada V; Gagnier P; Morrill B
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):302-6. PubMed ID: 21502969
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride/tamsulosin: in benign prostatic hyperplasia.
Keating GM
Drugs Aging; 2012 May; 29(5):405-19. PubMed ID: 22550968
[TBL] [Abstract][Full Text] [Related]
8. [Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction].
Kamalov AA; Takhirzade AM
Urologiia; 2018 Jul; (3):70-77. PubMed ID: 30035422
[TBL] [Abstract][Full Text] [Related]
9. [Additional administration of dutasteride in patients with benign prostatic hyperplasia who did not respond sufficiently to α1-adrenoceptor antagonist : investigation of clinical factors affecting the therapeutic effect of dutasteride].
Masuda M; Murai T; Osada Y; Kawai M; Kasuga J; Yokomizo Y; Kuroda S; Nakamura M; Noguchi G
Hinyokika Kiyo; 2014 Feb; 60(2):61-7. PubMed ID: 24755815
[TBL] [Abstract][Full Text] [Related]
10. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
World J Urol; 2021 Jul; 39(7):2635-2643. PubMed ID: 33337513
[TBL] [Abstract][Full Text] [Related]
11. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
Chung BH; Lee SH; Roehrborn CG; Siami PF; Major-Walker K; Wilson TH; Montorsi F;
Int J Urol; 2012 Nov; 19(11):1031-5. PubMed ID: 22774774
[TBL] [Abstract][Full Text] [Related]
13. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
[TBL] [Abstract][Full Text] [Related]
15. Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement.
Ismail M; Hashim H
Drugs Today (Barc); 2012 Jan; 48(1):17-24. PubMed ID: 22384457
[TBL] [Abstract][Full Text] [Related]
16. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
[TBL] [Abstract][Full Text] [Related]
17. Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha-1-adrenergic antagonists and 5-alpha-reductase inhibitors.
Zitoun OA; Farhat AM; Mohamed MA; Hamad MR; Aramini B; Haider KH
Eur J Pharmacol; 2020 Sep; 883():173301. PubMed ID: 32592768
[TBL] [Abstract][Full Text] [Related]
18. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
19. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
[TBL] [Abstract][Full Text] [Related]
20. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
